Title :

Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party.

Author(s) :

Bazarbachi, Ali [Auteur]
American University of Beirut Faculty of Medicine and Medical Center [AUB]
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Remenyi, Peter [Auteur]
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet [Budapest, Hungary]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Kröger, Nicolaus [Auteur]
Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] [UKE]
Socié, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Craddock, Charles [Auteur]
Queens Elizabeth Hospital [Birmingham]
Bourhis, Jean Henri [Auteur]
Institut Gustave Roussy [IGR]
Versluis, Jurjen [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Salmenniemi, Urpu [Auteur]
El-Cheikh, Jean [Auteur]
American University of Beirut Faculty of Medicine and Medical Center [AUB]
Bug, Gesine [Auteur]
Goethe University Frankfurt
Esteve, Jordi [Auteur]
Institut d'Investigacions Biomèdiques August Pi i Sunyer [IDIBAPS]
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Ciceri, Fabio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Clinical Cancer Research

Abbreviated title :

Clin Cancer Res

Publication date :

2023-08-22

ISSN :

1557-3265

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Purpose: Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended in first complete remission (CR1) in patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3–internal tandem ...
Show more >Purpose: Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended in first complete remission (CR1) in patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD). We assessed changes over time in transplant characteristics and outcomes in patients with AML age 60 years and younger with a FLT3-ITD. Experimental Design: We identified 1,827 adult patients with AML (median age 49 years, range 18–60) with FLT3-ITD and intermediate karyotype, allografted between 2012 and 2021 in CR1. Results: NPM1 was mutated in 72% of patients. We compared changes over time in 688 patients transplanted between 2012 and 2016, and 1,139 patients transplanted between 2017 and 2021. For patients with wild-type NPM1, the 2-year leukemia-free survival (LFS) and overall survival (OS) significantly improved over time from 54% to 64% (HR = 0.67; P = 0.011) and from 63% to 71% (HR = 0.66; P = 0.021), respectively. Allo-HCT in recent years significantly reduced the cumulative incidence of relapse (CIR). For patients with NPM1 mutation, no significant changes over time were noted. Conclusions: In patients with AML with FLT3-ITD and wild-type NPM1, we noticed a significant decrease over time in the CIR and improvement of LFS and OS, likely reflecting the efficacy of FLT-3 inhibitors, including when used as posttransplant maintenance, in this high-risk setting. On the contrary, no significant change over time was noticed in outcomes of patients harboring a FLT3 and NPM1 mutation.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-06T22:30:21Z
2024-03-19T14:36:13Z